Search company, investor...


Founded Year



Acquired | Acquired

Total Raised




About Alveolus

Alveolus is a developer of non- vascular interventional stent technology. Alveolus' stenting technology enhances the quality of life for patients who suffer from pulmonary or gastrointestinal obstruction. The Alveolus product ideation process allows for rapid prototyping and development of products to address the specific requirements for each area of the body.

Headquarters Location

9013 Perimeter Woods Suite A

Charlotte, North Carolina, 28216,

United States

Missing: Alveolus's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Alveolus's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Alveolus Patents

Alveolus has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics




Implants (medicine), Digestive system, Interventional cardiology, Prosthetics, Arteries of the lower limb


Application Date


Grant Date



Related Topics

Implants (medicine), Digestive system, Interventional cardiology, Prosthetics, Arteries of the lower limb



Latest Alveolus News

Merit Medical Announces Agreement to Acquire Assets of Alveolus, Inc.

Aug 30, 2013

Merit Also Signs Agreement to Acquire Products of Biosearch Medical Products, Inc. SOUTH JORDAN, Utah, Feb 19, 2009 (GlobeNewswire via COMTEX) -- Merit Medical Systems, Inc. (Nasdaq:MMSI), a manufacturer and marketer of proprietary disposable devices used primarily in cardiology and radiology procedures, announced today that it has signed a definitive agreement to acquire the assets of Alveolus, Inc., located in Charlotte, North Carolina. Alveolus produces non-vascular interventional stents used for esophageal, tracheobronchial, and biliary stenting procedures. Merit believes the current worldwide market for these types of products exceeds $200 million. The purchase price of the Alveolus assets is approximately $19 million, subject to post-closing adjustments. The Alveolus assets consist primarily of an intellectual property portfolio, inventory, receivables and manufacturing equipment. Alveolus' revenues for the most recent 12-month period (February 1, 2008 to January 31, 2009) were approximately $8.2 million. Merit intends to fund the purchase price from its existing cash reserves. Merit intends to hire essentially all of Alveolus' existing U.S. sales force of approximately ten individuals and several research and development and manufacturing personnel. "For several years we have discussed the prospects of entering the gastroenterology and pulmonary markets," said Fred P. Lampropoulos, Merit's Chairman and Chief Executive Officer. "We believe this acquisition will enhance our future corporate growth with products that are well accepted in the United States. The acquired products are also CE marked, and we believe our infrastructure and long-standing reputation for service and quality products in the European market will provide opportunities for substantial growth of the Alveolus products. " Substantially all of the manufacturing processes of the Alveolus stents are outsourced under manufacturing, confidentiality and performance agreements. Merit intends to maintain the relationships with these vendors and to retain the existing agreements. "A key feature of this acquisition is the operational consistency we believe we will maintain during the transition of ownership," Lampropoulos said. Inflation devices, guide wires and syringes are often used during gastroenterology procedures. Merit believes that many of its quality products in these categories can be sold in conjunction with the acquired products. Merit also announced that it has entered into an agreement with Biosearch Medical Products, Inc., a wholly-owned subsidiary of Hydromer, Inc. (OTCBB:HYDI), to acquire two additional products that are being sold on an OEM basis to major medical device companies. These products go hand-in-hand with the strategy of building a strong product offering in the gastroenterology market. The Biosearch transaction involves the transfer of production to a Merit facility. The purchase price is approximately $1.6 million, which Merit also intends to fund from its existing cash reserves. "In addition to the announced acquisitions, Merit is pursuing additional product distribution opportunities to complement the acquired products," Lampropoulos said. "With Merit's existing products, as well as the newly acquired products and the future opportunities we have identified, we believe a worldwide market opportunity of more than $500 million exists," Lampropoulos said. "We believe the combined revenue base of approximately $8.2 million for Alveolus' stent products and $1.6 million for Biosearch's accessory products will create margins in excess of Merit's existing gross margins and should add 80 to 100 basis points to Merit's gross margins annually," Lampropoulos said. "We believe additional margin expansion is possible as the business grows. " Merit plans to form a new business unit to focus on the newly-acquired products and opportunities, which will be led by Darla Gill, a founder and current Executive Vice President of Marketing at Merit. Gill's experience and skills uniquely qualify her to oversee the growth and expansion of this new business segment. "Merit believes that with the existing Alveolus sales force, the additional sales people we intend to hire, and the selection of dealers in non-direct geographic areas, the new business segment can grow by 40-50% for the next few years," Lampropoulos added. Most biliary stents are currently placed endoscopically by gastroenterologists. A portion of the biliary stents, however, is placed percutaneously by interventional radiologists. Merit intends to aggressively pursue the interventional radiology segment with its existing interventional radiology sales force. Aside from the newly acquired products, Merit believes another long-term benefit of the Alveolus acquisition is the general stent technology platform that Merit will develop for future vascular and non-vascular products. Although this is some time away and will require substantial development and regulatory approvals, Merit believes the fundamental technology can be further organized and directed. Both transactions are expected to close in the next 30 days. Piper Jaffray consulted with Merit in both transactions, while Canaccord Adams Inc. advised Alveolus. CONFERENCE CALL Merit invites all interested parties to participate in its conference call today, (Thursday, February 19, 2009) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). The telephone numbers to call are (domestic) 800-218-8862; and (international) 303-262-2130. A live webcast will also be available for the conference call at and During the conference call, the information set forth in this release will be discussed in more detail. ABOUT MERIT Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology and radiology. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 100 individuals. Merit employs approximately 1,700 people worldwide, with facilities in Salt Lake City and South Jordan, Utah; Angleton, Texas; Richmond, Virginia; Maastricht and Venlo, The Netherlands; and Galway, Ireland. The Merit Medical Systems, Inc. logo is available at Statements contained in this release which are not purely historical, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties such as those described in Merit's Annual Report on Form 10-K for the year ended December 31, 2007. Such risks and uncertainties include risks relating to the closing of the proposed Alveolus and Biosearch transactions, including the possibility that conditions to closing those transactions may not be satisfied or that either or both of those transactions may not be completed; unanticipated consequences of Merit's proposed acquisition of the Alveolus and Biosearch assets; challenges associated with Merit's efforts to pursue new market opportunities, including opportunities in the gastroenterology and pulmonary markets; infringement of Merit's technology or the assertion that Merit's technology infringes the rights of other parties; product recalls and product liability claims; downturn of the national economy and its affect on Merit's revenues, collections and supplier relations; termination of supplier relationships, or failure of suppliers to perform; inability to successfully manage growth through acquisitions; delays in obtaining regulatory approvals, or the failure to maintain such approvals; concentration of Merit's revenues among a few products and procedures; development of new products and technology that could render Merit's products obsolete; market acceptance of new products; introduction of products in a timely fashion; price and product competition; availability of labor and materials; cost increases; and fluctuations in and obsolescence of inventory; volatility of the market price of Merit's common stock; foreign currency fluctuations; changes in key personnel; work stoppage or transportation risks; modification or limitation of governmental or private insurance reimbursement; changes in health care markets related to health care reform initiatives; and other factors referred to in Merit's Annual Report on Form 10-K for the year ended December 31, 2007, and other reports filed with the Securities and Exchange Commission. All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and Merit assumes no obligation to update or disclose revisions to those estimates. This news release was distributed by GlobeNewswire, SOURCE: Merit Medical Systems, Inc. Merit Medical Systems, Inc. Anne-Marie Wright, Vice President, Corporate Communications (801) 208-4167 Fax: (801) 253-1688

Alveolus Frequently Asked Questions (FAQ)

  • When was Alveolus founded?

    Alveolus was founded in 2001.

  • Where is Alveolus's headquarters?

    Alveolus's headquarters is located at 9013 Perimeter Woods, Charlotte.

  • What is Alveolus's latest funding round?

    Alveolus's latest funding round is Acquired.

  • How much did Alveolus raise?

    Alveolus raised a total of $28M.

  • Who are the investors of Alveolus?

    Investors of Alveolus include Merit Medical, MB Venture Partners, HealthCare Capital Partners, Clayton Associates, Lumira Ventures and 5 more.

  • Who are Alveolus's competitors?

    Competitors of Alveolus include Svelte Medical Systems, Endologix, Tryton Medical, ArraVasc, BARRx Medical and 9 more.

Compare Alveolus to Competitors

Micell Technologies

Micell Technologies aims to bring together the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent.

Endologix Logo

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.


SquareOne is developing a stent delivery system.

TriReme Medical

TriReme Medical is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.

Svelte Medical Systems

Svelte Medical Systems is engaged in the development of highly deliverable balloon expandable stents. The Svelte IDS is designed to realize the clinical, time and cost-savings benefits of direct stenting in a single platform. Svelte is developing a Sirolimus eluting stent that has non-inflammatory properties, potentially making it less irritating to the vessel lining than stents with typical polymeric coatings. The Svelte DES is being developed to have the same drug release kinetics as the market leaders while potentially minimizing inflammation in the vessel to reduce the need for long term dual anti-platelet therapy.

Reva Medical

REVA Medical develops interventional medical devices that leverage the company's stent designs and biomaterials to improve the treatment of vascular disease. Its flagship product is called MOTIV, a bioresorbable coronary stent that is designed to fulfill the temporary need for a stent and then fade away, leaving only the healed vessel behind. This product is utilized for the treatment of coronary artery disease. REVA Medical has a broad strategic relationship with Boston Scientific Corporation, a worldwide developer and marketer of interventional medical devices. The company was founded in 1998 and is based in San Diego, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.